Skip to content
Screener

EPS (Diluted) at other companies

HRO
HarrowHROW
-$0.46-454%
XER
Xeris Biopharma Holdings, Inc.XERS
-$0.18-1,700%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.05+192%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$0.90+23.1%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0.14-88.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$0.44-30.2%

Other financials

Income statement

See full
Revenue$37.6M+98.6%
Gross profit$25.4M+113%
Operating income$12.8M+967%
Net income$11.6M+548%

Balance sheet

See full
Cash & equivalents$26.8M+5.8%
Total debt$28.8M-6.3%
Total equity$46.6M+94.4%
Total assets$115.8M+13.9%

Cash flow

See full
Operating cash flow$7.3M-8.8%
CapEx$75.0K—
Free cash flow$7.3M-8.8%

Valuation

See full
Market cap$1.47B+180%
Enterprise value$1.47B+184%
P/E170.7×—
P/S13.9×+6.5×

Profitability

See full
Gross margin57.9%-1.5pp
Operating margin-15.1%—
Net margin-9.5%-2.7pp
FCF margin17.1%—

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity0.6×-0.7×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed August 13, 2026.

Filed
Aug 13, 2026, 4:16 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001437749-26-027684
Line itemFor the three months ended / June 30, 2026For the three months ended / June 30, 2025For the six months ended / June 30, 2026For the six months ended / June 30, 2025
Interest and other expense, net(1,076)(1,044)(1,916)(2,072)
Income (loss) before income tax expense11,718(2,519)13,292(4,017)
Income tax expense14066160140
Net income (loss)$11,578$(2,585)$13,132$(4,157)
Net income (loss) per share, basic$0.42$(0.10)$0.48$(0.15)
Weighted average number of common shares outstanding, basic27,64226,89327,44426,889
Net income (loss) per share, diluted$0.35$(0.10)$0.41$(0.15)
Weighted average number of common shares outstanding, diluted32,78726,89332,29826,889

Document

FAQ

What is Eton Pharmaceuticals, Inc.'s EPS (diluted)?
Eton Pharmaceuticals, Inc. (ETON) reported EPS (diluted) of $0.35 in Q2 2026.
How has Eton Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
Eton Pharmaceuticals, Inc.'s EPS (diluted) increased by 450.0% year-over-year, from -$0.10 to $0.35.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Eton Pharmaceuticals, Inc.'s eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude